General Information of Drug (ID: DMLN0Y5)

Drug Name
Alvameline Drug Info
Synonyms Alvameline maleate; LU-25077; LU-25109; LU-31126; LU-32181; Lu-25109M
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Terminated [1]
Cross-matching ID
PubChem CID
178030
CAS Number
CAS 120241-31-8
TTD Drug ID
DMLN0Y5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [2]
Fesoterodine fumarate DM13495 Overactive bladder GC50.0 Approved [3]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [4]
Clidinium DMUMQZ0 Abdominal stomach pain DD91.4 Approved [5]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [6]
Oxyphenonium DMMQHOZ Visceral spasms MD81.4 Approved [7]
Benztropine DMGZOVN Parkinson disease 8A00.0 Approved [8]
Glycopyrrolate DM2M3ZA Anaesthesia 9A78.6 Approved [9]
Pirenzepine DMP6M1N Peptic ulcer DA61 Approved [10]
Cycrimine DM8C43Q Parkinson disease 8A00.0 Approved [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [2]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [12]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [4]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [13]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [14]
FP-1097 DMC1F2T Urinary incontinence MF50.2 Phase 2 [15]
PSD-506 DMT0KB1 Overactive bladder GC50.0 Discontinued in Phase 2 [16]
Otenzepad DMRXHAC Heart failure BD10-BD13 Discontinued in Phase 2 [17]
SCH-211803 DM92E0W Parkinson disease 8A00.0 Discontinued in Phase 1 [18]
HIMBACINE DMGAKD8 N. A. N. A. Terminated [19]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolterodine DMSHPW8 Overactive bladder GC50.0 Approved [20]
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [2]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [21]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [22]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [23]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [24]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [4]
Solifenacin DMG592Q Overactive bladder GC50.0 Approved [25]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [26]
Cevimeline DMWSMND Sjogren syndrome 4A43.20 Approved [27]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Modulator [1]
Muscarinic acetylcholine receptor M2 (CHRM2) TTYEG6Q ACM2_HUMAN Modulator [1]
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Modulator [1]

References

1 In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
2 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
5 Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
6 The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
7 Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
8 Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
9 Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
10 Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
11 Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
12 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
13 Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
14 Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
15 Clinical pipeline report, company report or official report of FemmePharma.
16 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
17 Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
18 Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
19 Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.
20 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
21 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
22 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
23 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
24 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
25 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
26 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
27 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.